Corvus Pharmaceuticals, Inc. (CRVS)
Total Valuation
CRVS has a market cap or net worth of $40.50 million. The enterprise value is -$19.05 million.
| Market Cap | 40.50M |
| Enterprise Value | -19.05M |
Important Dates
The next earnings date is Monday, August 1, 2022, before market open.
| Estimated Earnings Date | Aug 1, 2022 |
| Ex-Dividend Date | n/a |
Share Statistics
CRVS has 46.55 million shares outstanding. The number of shares has increased by 34.88% in one year.
| Shares Outstanding | 46.55M |
| Shares Change (YoY) | +34.88% |
| Shares Change (QoQ) | -0.11% |
| Owned by Insiders (%) | 3.72% |
| Owned by Institutions (%) | 59.29% |
| Float | 28.77M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | n/a |
| PB Ratio | 0.45 |
| P/FCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 6.95, with a Debt / Equity ratio of 0.04.
| Current Ratio | 6.95 |
| Quick Ratio | 6.83 |
| Debt / Equity | 0.04 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
Financial Efficiency
Return on equity (ROE) is -41.10%, which is considered low. The company has a ROIC of -87.10%.
| Return on Equity (ROE) | -41.10% |
| Return on Assets (ROA) | -36.40% |
| Return on Capital (ROIC) | -87.10% |
| Revenue Per Employee | n/a |
| Profits Per Employee | -$1.43M |
| Employee Count | 28 |
| Asset Turnover | n/a |
| Inventory Turnover | n/a |
Taxes
| Income Tax | n/a |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -63.96% in the last 52 weeks. The beta is 1.07, so CRVS's price volatility has been similar to the market average.
| Beta (1Y) | 1.07 |
| 52-Week Price Change | -63.96% |
| 50-Day Moving Average | 1.04 |
| 200-Day Moving Average | 1.69 |
| Average Volume (30 Days) | 268,482 |
Short Selling Information
The latest short interest is 191,612, so 0.41% of the outstanding shares have been sold short.
| Short Interest | 191,612 |
| Short % of Shares Out | 0.41% |
| Short % of Float | 0.67% |
| Short Ratio (days to cover) | 0.91 |
Income Statement
| Revenue | n/a |
| Gross Profit | n/a |
| Operating Income | -34.56M |
| Net Income | -39.96M |
| EBITDA | -39.55M |
| EBIT | -39.96M |
| Earnings Per Share (EPS) | -$0.89 |
Balance Sheet
The company has $62.94 million in cash and $3.39 million in debt, giving a net cash position of $59.55 million or $1.28 per share.
| Cash & Cash Equivalents | 62.94M |
| Total Debt | 3.39M |
| Net Cash | 59.55M |
| Net Cash Per Share | $1.28 |
| Book Value | 89.72M |
| Book Value Per Share | 1.93 |
| Working Capital | 55.10M |
Cash Flow
In the last 12 months, operating cash flow was -$34.35 million and capital expenditures -$5,000, giving a free cash flow of -$34.36 million.
| Operating Cash Flow | -34.35M |
| Capital Expenditures | -5,000 |
| Free Cash Flow | -34.36M |
| FCF Per Share | n/a |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
CRVS does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Earnings Yield | -98.66% |
| FCF Yield | -84.83% |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -34.88% |
| Shareholder Yield | -34.88% |
Analyst Forecast
The average price target for CRVS is $6.50, which is 647.13% higher than the current price. The consensus rating is "Buy".
| Price Target | $6.50 |
| Price Target Difference | 647.13% |
| Analyst Consensus | Buy |
| Analyst Count | 10 |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |